SecBot SecBot
8-K ·Filed Nov 13, 2026

MEDS

DataMeds AI, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed4d 1h ago SEC0001493152-26-051734
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The sequential revenue growth and Nasdaq compliance restoration are positive, but the net profit is entirely from a non-cash debt extinguishment gain and cash is burning quickly ($0.48M vs $2.46M last quarter). Watch for the conversion of the HMO MOU into a definitive agreement and whether Corexa Pharmacy's revenue growth can sustain without further dilution or debt restructuring.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.6421
T+0 close · Nov 13, 2026 · via day close
Latest settled
−0.28%
T+1 · $0.6403
Vs SPY
+0.73%
α at T+1
Next horizon
T+5
in 6d
  1. T+0 · Nov 16 $0.6421entry
  2. T+1 · 11h ago −0.28%α +0.73% · $0.6403
  3. T+5 · in 6d Pending
  4. T+20 · in 28d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

DataMEDS AI reported Q3 2026 revenue of $2.67 million, up 50% sequentially from Q2 2026's $1.78 million, and generated GAAP net income of $10.5 million ($2.72 diluted EPS) versus a $34.3 million loss a year ago, driven by a $19.1 million gain on debt extinguishment. The company also regained full Nasdaq compliance, launched the Health Lives Here app with NFL Alumni Health, and signed an MOU with a Florida HMO covering 25,000+ members. However, revenue declined 11.4% YoY from $3.01 million, and the net profit was entirely from non-operating debt gains, with a $3.4 million operating loss.

Key Financial Metrics

EPS
$2.72
Revenue
$2.7M
-11.4% YoY
Gross Margin
16.2%

Key Facts

  • Q3 2026 revenue of $2,668,980, up 50% sequentially from Q2 2026's $1,779,860 but down 11.4% from $3,012,904 in Q3 2025
  • GAAP net income of $10,535,560 ($2.72 diluted EPS) vs net loss of $34,318,204 ($23.07 loss per share) in Q3 2025
  • Net income driven by $19,064,881 gain on extinguishment of debt; operating loss was $3,373,956
  • Cash and cash equivalents fell to $476,598 from $2,456,373 at June 30, 2026
  • Regained full compliance with Nasdaq listing standards on October 19, 2026
  • Launched Health Lives Here mobile app with NFL Alumni Health marketing platform
  • Signed non-binding MOU with Florida HMO to deploy app to 25,000+ members
  • Acquired Helomics cancer diagnostics laboratory in September 2026
  • Obtained exclusive license to REBOOT GLP-1 patient management platform in October 2026
  • Corexa Pharmacy launched compounded peptides under FDA Enforcement Discretion Policy in November 2026

Financial Impact

Revenue $2.67M (Q3 2026), GAAP net income $10.5M, operating loss $3.4M, cash $0.48M

revenuenet incomecashoperating loss

Risk Factors

  • Cash balance of $476,598 is very low relative to current liabilities of $37.9M, raising going-concern risk
  • Revenue declined 11.4% YoY; the sequential growth is from a low base and may not be sustainable
  • Net profit is entirely from a non-operating $19.1M debt extinguishment gain; operating loss of $3.4M persists
  • Convertible notes payable increased to $15.3M from zero at year-end 2025, adding dilution risk
  • HMO MOU is non-binding and may not result in a definitive agreement

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-051734
Document: form8-k.htm0001493152-26-051734
Document: 0001493152-26-051734-index-headers.html0001493152-26-051734
Document: 0001493152-26-051734-index.html0001493152-26-051734
Document: 0001493152-26-051734.txt0001493152-26-051734
8-K Data (Synthetic)0001493152-26-051734

Track record

15 reports on MEDS

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +35.05% at T+60 after the Aug 18, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 17, 2026today 424B5 Bearish 6/10 Entry price pending
  2. Nov 17, 2026today 8-K Bearish 7/10 Entry $0.6151 Now $0.6403 −4.10% settles Nov 25
  3. Nov 16, 20261d ago 424B5 Bearish 5/10 Entry $0.6421 Now $0.6403 +0.28% settles Nov 23
  4. Nov 16, 20261d ago 8-K Neutral 3/10 Entry $0.6421 Now $0.6403 −0.28% settles Nov 23
  5. Nov 13, 20264d ago 8-K Neutral 5/10 Viewing Entry $0.6421 Now $0.6403 −0.28% settles Nov 23
  6. Nov 10, 20266d ago SC 13G Neutral 4/10 Entry $0.9531 Now $0.6403 −32.82% settles Nov 18
  7. Nov 10, 20267d ago S-1/A Bearish 6/10 Entry $0.9531 Now $0.6403 +32.82% settles Nov 18
  8. Nov 5, 202612d ago 8-K Neutral 4/10 Entry $1.22 to $0.8702 Now $0.6403 −47.52% ▼ −28.67% −31.96% vs SPY
  9. Oct 26, 202622d ago 8-K Bearish 6/10 Entry $2.06 to $1.80 Now $0.6403 +68.92% ▲ +12.62% +10.63% vs SPY
  10. Oct 20, 202628d ago 8-K Neutral 4/10 Entry $2.75 to $2.06 Now $0.6403 −76.72% ▼ −25.09% −25.17% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026